Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Psychopharmacology (Berl). 2010 Jun 25;211(3):303–312. doi: 10.1007/s00213-010-1898-4

Figure 1.

Figure 1

Peak change from baseline means (±SEM) for visual analog item Drug Effect, observer rated Agonist, and pupil diameter for doses of hydromorphone (2, 4 mg), buprenorphine (4, 8, and 16 mg), and buprenorphine/naloxone (4/2, 8/4, and 16/8 mg). * p≤0.05 versus placebo.